Información del artículo
Resumen
Los fármacos opioides permanecen como fármacos de elección en el tratamiento del dolor agudo postoperatorio y del dolor crónico oncológico. Su prescripción inadecuada, ha dado lugar, en algunos países, a una verdadera «crisis de opioides». En este contexto, puede resultar interesante el potencial terapéutico de algunos ligandos que actúan como moduladores alostéricos de la fijación de los agonistas opioides y su capacidad de modular su actividad, modificando su afinidad, potencia e incluso eficacia.
Palabras clave:
Fármacos opioides
Dolor
Receptor opioide
Efectos adversos opioides
Abstract
Opioids are still the drugs of choice for the treatment of acute post-surgical pain and chronic cancer pain. Overprescribing of these drugs has given rise to an “opioid crisis” in some countries. In this context, attention has been drawn to the therapeutic potential of various ligands that act as allosteric modulators of orthosteric binding sites and modulate the drug's activity, affinity, potency, and even efficacy.
Keywords:
Opioids
Pain
Opioid receptor
Opioid side effects
Artículo
Opciones para acceder a los textos completos de la publicación Revista Española de Anestesiología y Reanimación
Suscriptor
Comprar
Contactar
Teléfono para suscripciones e incidencias
De lunes a viernes de 9h a 18h (GMT+1) excepto los meses de julio y agosto que será de 9 a 15h
Llamadas desde España
932 415 960
Llamadas desde fuera de España
+34 932 415 960
E-mail
Bibliografía
[1]
R. Vallejo, R.L. Barkin, V.C. Wang.
Pharmacology of opioids in the treatment of chronic pain syndromes.
Pain Physician., 14 (2011), pp. E343-E360
[2]
E. McNicol, N. Horowicz-Mehler, R.A. Fisk, K. Bennett, M. Gialeli-Goudas, P.W. Chew, et al.
Management of opioid side effects in cancer-related and chronic noncancer pain: A systematic review.
J Pain., 4 (2003), pp. 231-256
[3]
N.D. Volkow, A.T. McLellan.
Opioid abuse in chronic pain — Misconceptions and mitigation strategies.
N Engl J Med., 374 (2016), pp. 1253-1263
[4]
M. Spetea, H. Schmidhammer.
Opioids and their receptors: Present and emerging concepts in opioid drug discovery.
Molecules., 25 (2020), pp. 5658-5663
[5]
M.H. Ossipov, J. Lai, T. King, T.W. Vanderah, F. Porreca.
Underlying mechanisms of pronociceptive consequences of prolonged morphine exposure.
Biopolymers., 80 (2005), pp. 319-324
[6]
E.M. Jutkiewicz.
The antidepressant -like effects of delta-opioid receptor agonists.
Molecular Interventions., 6 (2006), pp. 162-169
[7]
I. Gomes, A. Gupta, J. Filipovska, H.H. Szeto, J.E. Pintar, L.A. Devi.
A role for heterodimerization of mu and delta opiate receptors in enhancing morphine analgesia.
Proc Natl Acad Sci USA., 101 (2004), pp. 5135-5139
[8]
N.R. Lenard, D.J. Daniels, P.S. Portoghese, S.C. Roerig.
Absence of conditioned place preference or reinstatement with bivalent ligands containing mu-opioid receptor agonist and delta-opioid receptor antagonist pharmacophores.
Eur J Pharmacol., 566 (2007), pp. 75-82
[9]
R.J. Valentino, N.D. Volkow.
Untangling the complexity of opioid receptor function.
Neuropsychopharmacol., 43 (2018), pp. 2514-2520
[10]
A. Christoph, M.H. Eerdekens, M. Kok, G. Volkers, R. Freynhagen.
Cebranopadol, a novel first-in-class analgesic drug candidate: First experience in patients with chronic low back pain in a randomized clinical trial.
Pain., 158 (2017), pp. 1813-1824
[11]
H. Ding, N. Kiguchi, D. Yasuda, P. Daga, W.E. Polgar, J. LU, et al.
A bifunctional nociceptin and mu opioid receptor agonist is analgesic without opioid side effects in nonhuman primates.
Sci Transl Med., 456 (2018), pp. 1-11
[12]
K.E. Livingston, J.R. Traynor.
Allostery at opioid receptors: Modulation with small molecule ligands.
Br J Pharmacol., 175 (2018), pp. 2846-2856
[13]
N.T. Burford, J.R. Traynor, A. Alt.
Positive allosteric modulators of the mu-opioid receptor: A novel approach for future pain medications.
Br J Pharmacol., 172 (2015), pp. 277-286
[14]
M. Kathmann, K. Flau, A. Redmer, C. Trankle, E. Schlicker.
Cannabidiol is an allosteric modulator at mu- and delta-opioid receptors.
Naunyn-Schmiedeberg's Arch Pharmacol., 372 (2006), pp. 354-361
[15]
R.B. Rothman, D.L. Murphy, H. Xu, J.A. Godin, C.M. Dersch, J.S. Partilla, et al.
Salvinorin A: Allosteric interactions at the mu-opioid receptor.
J Pharmacol Exp Ther., 320 (2007), pp. 801-810
[16]
L.M. Bohn, R.R. Gainetdinov, F.T. Lin, R.J. Lefkowitz, M.G. Caron.
Mu-opioid receptor desensitización by beta-arrestin-2 determines morphine but not dependence.
Nature., 408 (2000), pp. 720-723
[17]
K. Miyano, S. Manabe, A. Komatsu, Y. Fujii, Y. Mizobuchi, E. Uezono, et al.
The G protein signal-biased compound TRV130; structures, its site of action and clinical studies.
Curr Top Med Chem., 20 (2021), pp. 2822-2829
[18]
X. Li, W. He, Y. Chen, G. Yang, H. Wan, L. Zhang, et al.
Discovery of SHR9352: A highly potent G protein-biased μ-opioid receptor agonist ACS omega, 2 (2017), pp. 9261-9267
[19]
A. Váradi, G.F. Marrone, T.C. Palmer, A. Narayan, M.R. Szabo, V. Le Rouzic, et al.
Mitragynine/corynantheidine, pseudoindoxyls as opioid analgesics with mu agonism and delta antagonism, which do not recruit β-arrestin-2.
J Med Chem., 59 (2016), pp. 8381-8397
[20]
M. Remesic, B.J. Hruby, F. Porreca, Y.S. Lee.
Recent advances in the realm of allosteric modulators for opioid receptors for the future therapeutics.
ACS Chem Neurosci., 8 (2017), pp. 1147-1158
[21]
D. Bartuzi, E. Kedzierska, A. Kaczor, H. Schmidhammer, D. Matosiuk.
Novel positive allosteric modulators of μ opioid receptor —Insight from in silico and in vivo studies.
Int J Mol Sci., 21 (2020), pp. 8463-8478
[22]
A. Faouzi, B.R. Varga, S. Majumdar.
Biased opioid ligands.
Molecules., 25 (2020), pp. 4257
[23]
D. Bartuzi, T.M. Wróbel, A. Kaczor, D. Matosiuk.
Tuning down the pain —An overview of allosteric modulation of opioid receptors: Mechanisms of modulation, allosteric sites, modulator syntheses.
Curr Top Med Chem., 20 (2021), pp. 2852-2865
[24]
A. Azzam, J. McDonald, D.G. Lambert.
Hot topics in opioid pharmacology: Mixed and biased opioids.
Brith J Anesth., 122 (2019), pp. 705-707
[25]
X. Cong, D. Maurel, H. Demene, I.V. Brooks, J. Hagelberger, F. Peyson, et al.
Molecular insights into the biased signaling mechanism of the u-opioid receptor.
Molecular Cell., 81 (2021), pp. 4165-4175
